Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Málaga
Clinical trial register · Spain

Clinical Trials in Málaga, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5875
Studies in scope
all four open statuses
3096
Recruiting now
open to new participants
1137
Lead sponsors
across recruiting studies
Top sites
Barcelona 3238 Madrid 3046 Valencia 1215 Seville 1054 Málaga 746
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca66 Janssen Research & Development, LLC30 Merck Sharp & Dohme LLC29 Hoffmann-La Roche28 Bristol-Myers Squibb26
Site location
Barcelona3238 Madrid3046 Valencia1215 Seville1054 Málaga746
All 453 locations
Target enrolment
to

Trials with a site in Málaga

746 of 5875 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Not yet open
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Jaén, Málaga, Palma de Mallorca, Salamanca, Barcelona, L'Hospitalet de Llobregat, Valencia, A Coruña
2027-11-23
Not yet open
Fernando Pessoa Canarias University
Not applicable
60
Las Palmas de Gran Canaria, Málaga
2027-03-31
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
A Coruña, Barcelona, Málaga
2027-02-03
Not yet open
Bristol-Myers Squibb
Phase 3
2,380
Santander, Santiago de Compostela, Barcelona, Coslada, Girona, Madrid, Málaga, Oviedo
2026-12-16
Not yet open
Boehringer Ingelheim
Phase 3
270
Barcelona, Madrid, Málaga, Valencia
2026-11-09
Not yet open
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Not applicable
150
Málaga
2026-11-01
Not yet open
PETHEMA Foundation
Phase 2
30
Seville, Valencia, Badalona, Barcelona, Madrid, Málaga, Salamanca, San Sebastián
2026-10-30
Recruiting
A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.
NCT07559175Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases
DrugZenpep
Aimmune Nestlé Health Science US R&D, LLC
Phase 2
66
Madrid, Murcia, Lleida, Málaga, Valencia
2026-10
Recruiting
Spanish Breast Cancer Research Group
Observational
300
San Sebastián, Barcelona, Madrid, Málaga, Seville, Toledo, Valencia
2026-09-30
Not yet open
University of Malaga
Observational
60
Málaga
2026-09-26
Recruiting
Daiichi Sankyo
Phase 1/2
220
Badalona, Barcelona, Granada, Madrid, Málaga, Pamplona, Pozuelo de Alarcón, Santa Cruz de Tenerife
2026-09-17
Not yet open
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Not applicable
200
Málaga
2026-09-15
Recruiting
Vividion Therapeutics, Inc.
Phase 2
140
Santiago de Compostela, Barcelona, Madrid, Málaga, Valencia
2026-09-11
Recruiting
Bristol-Myers Squibb
Phase 2
160
Badalona, Seville, Barcelona, Madrid, Majadahonda, Málaga
2026-09-10
Recruiting
Takeda
Phase 3
324
Badalona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Málaga, Barcelona, Madrid, Salamanca, Valencia
2026-09-10
Recruiting
Incyte Corporation
Phase 3
426
Alicante, Barcelona, Bilbao, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga
2026-09-08
Recruiting
Bristol-Myers Squibb
Phase 3
850
Majadahonda, Seville, A Coruña, Jaén, Jerez de la Frontera, Madrid, Málaga, Valencia
2026-09-08
Not yet open
Gruppo Oncologico del Nord-Ovest
Phase 3
244
Barcelona, Madrid, Málaga, Ourense, Pamplona, Santander, Valencia, Zaragoza
2026-09-01
Not yet open
Foot and Ankle Strengthening Program to Improve Physical Function in Menopausal Women (FAMEX)
NCT07472205Menopause, Musculoskeletal Function, Physical Function
University of Malaga
Not applicable
70
Málaga
2026-09-01
Not yet open
Philippe ROUSSELOT
Phase 2
93
Barcelona, Madrid, Málaga, Murcia, Salamanca, San Sebastián, Santander, Seville
2026-09-01
Not yet open
Effects of Virtual Assistant Features on User Experience in Service Settings
NCT07666295User Experience With Virtual Assistants in Service Settings
University of Malaga
Not applicable
400
Málaga
2026-09
Not yet open
Eli Lilly and Company
Phase 3
150
Barcelona, Madrid, Málaga, Sabadell, Seville, Vitoria-Gasteiz
2026-09
Not yet open
Eli Lilly and Company
Phase 3
170
Barcelona, Málaga, Seville
2026-09
Not yet open
iVascular S.L.U.
Not applicable
45
Málaga, Zaragoza, Barcelona, L'Hospitalet de Llobregat, Vigo
2026-08-31
Not yet open
Telerehabilitation in Pulmonary Arterial Hypertension
NCT07799675Pulmonary Arterial Hypertension (PAH)
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Not applicable
34
Málaga
2026-08-30
Recruiting
Kardigan, Inc.
Phase 3
332
A Coruña, Barcelona, Madrid, Málaga, Murcia, Palma de Mallorca, Seville
2026-08-26
Recruiting
AstraZeneca
Phase 3
7,000
Badajoz, Barcelona, Burgos, Córdoba, Granada, Madrid, Majadahonda, Málaga
2026-08-21
Recruiting
MedSIR
Phase 1/2
278
Badalona, Barakaldo, Barcelona, Madrid, Málaga, San Cristóbal de La Laguna, Seville, Zaragoza
2026-08-20
Recruiting
AstraZeneca
Phase 3
1,500
A Coruña, Alzira, Barcelona, Ferrol, Lleida, Málaga, Oviedo, Segovia
2026-08-20
Recruiting
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
NCT07746895C3 Glomerulopathy (C3G), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
DrugPegcetacoplan
Swedish Orphan Biovitrum
Phase 4
150
A Coruña, Barcelona, Las Palmas, Madrid, Málaga, Valencia
2026-08-05
Recruiting
IDP Discovery Pharma S.L.
Phase 1/2
60
Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Murcia, Pamplona, Santa Cruz de Tenerife, Valencia
2026-07-28
Not yet open
Nelum Corp
Phase 2
40
Zaragoza, Barcelona, Santander, San Sebastián, Santiago de Compostela, Málaga
2026-07-15
Recruiting
UCB BIOSCIENCES, Inc.
Phase 3
200
Madrid, Málaga, Seville
2026-07-14
Recruiting
Boehringer Ingelheim
Phase 3
390
Badalona, Barcelona, Madrid, Málaga, Pamplona, Santander, Seville, Valencia
2026-07-10
Recruiting
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
NCT07683065Plaque Psoriasis, Metabolic Dysfunction-Associated Steatotic Liver Disease
Novartis Pharmaceuticals
Observational
150
Badalona, Barcelona, Madrid, Málaga
2026-07-08
Recruiting
AstraZeneca
Phase 3
900
Barcelona, Ferrol, Lleida, Madrid, Majadahonda, Málaga, Santander, Seville
2026-07-06
Recruiting
Dietary Approaches for the Management of Overweight and Obesity in Type 1 Diabetes
NCT07667504Type 1 Diabetes (T1D), Obesity & Overweight
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Not applicable
75
Málaga
2026-07-02
Recruiting
PETHEMA Foundation
Phase 3
376
Santiago de Compostela, Hospitalet Del Llobregat, Terrassa, Jaén, Alcalá de Henares, San Sebastián de los Reyes, Málaga, Barakaldo
2026-07-02
Not yet open
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
101
Badalona, Barcelona, Granada, Jaén, Málaga, Oviedo, Pamplona, Valencia
2026-07-01
Recruiting
SucroMet Nutritional Intervention Trial
NCT07656298Overweight , Obesity, Glucose Metabolism
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Not applicable
120
Málaga
2026-07
Recruiting
Nefro Avillion Clinical Development, LLC
Phase 2
120
Barcelona, Málaga
2026-06-29
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
960
Badalona, Málaga, Barcelona, Madrid, Salamanca
2026-06-22
Recruiting
Eikon Therapeutics
Phase 2/3
750
Jerez de la Frontera, Castellon, Barcelona, Girona, Málaga
2026-06-15
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Valencia
2026-06-11
Active, closed
AstraZeneca
Phase 2
326
Barcelona, Jaén, L'Hospitalet de Llobregat, Majadahonda, Málaga, Pamplona, Salamanca, Valencia
2026-06-11
Recruiting
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
NCT07504458Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
DrugsArsenic Trioxide·ATRA
Quetzal Therapeutics
Phase 3
150
Palma de Mallorca, Badalona, Barcelona, Cáceres, Málaga, Oviedo, Valencia
2026-06-08
Recruiting
Rovi Pharmaceuticals Laboratories
Phase 1
120
Alcorcón, Barcelona, Granada, Jaén, León, Lleida, Manresa, Málaga
2026-06-08
Not yet open
University of Malaga
Observational
50
Málaga
2026-06-05
Recruiting
Dompé Farmaceutici S.p.A
Phase 3
150
A Coruña, Cardona, Badalona, Barcelona, Madrid, Málaga, Seville, Valencia
2026-06-02
Recruiting
Bayer
Phase 3
117
Esplugues de Llobregat, Barcelona, Córdoba, Madrid, Málaga, Seville
2026-06-01
Recruiting
UCB Biopharma SRL
Phase 3
120
Alicante, Barcelona, Madrid, Málaga
2026-05-27
Recruiting
Hoffmann-La Roche
Phase 2/3
650
EL Palmar (EL Palmar), San Cristóbal de La Laguna, Bilbao, Barcelona, Granada, Jaén, Madrid, Málaga
2026-05-21
Recruiting
Novo Nordisk A/S
Phase 3
2,500
A Coruña, Antequera, Barcelona, Centelles (Barcelona), Girona, Madrid, Manresa, Málaga
2026-05-21
Recruiting
Takeda
Phase 3
300
L'Hospitalet de Llobregat, Seville, Barcelona, Madrid, Málaga, Salamanca, Valencia
2026-05-21
Recruiting
Incyte Corporation
Phase 2
60
Barcelona, Esplugues de Llobregat, Madrid, Málaga, Murcia, Valencia
2026-05-20
Recruiting
Hoffmann-La Roche
Phase 3
138
Barcelona, Madrid, Málaga, Seville, Valencia
2026-05-15
Recruiting
Effectiveness of Best Care Practices in Acute Stroke in Conventional Hospitalization (BEST CARE ICTUS_HC)
NCT07627399Stroke, Acute Stroke, Ischemic Stroke, Hemorrhagic Stroke
University of Malaga
Not applicable
700
Antequera, Marbella, Ronda, Málaga
2026-05-12
Recruiting
Sanofi
Phase 4
300
Barcelona, A Coruña, Madrid, San Cristóbal de La Laguna, Málaga, Sabadell
2026-05-12
Recruiting
AstraZeneca
Phase 3
670
Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Santiago de Compostela
2026-05-04
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
L'Hospitalet de Llobregat, Barakaldo, Barcelona, Málaga, Badajoz, Madrid, Seville, Valencia
2026-05-04
Recruiting
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
DrugMK-1045
Merck Sharp & Dohme LLC
Phase 1/2
280
Badalona, Málaga, Barcelona, Madrid
2026-05-03
Recruiting
Hoffmann-La Roche
Phase 3
360
Barcelona, Madrid, Málaga, Seville, Valencia
2026-04-27
Recruiting
Inhibikase Therapeutics
Phase 3
486
Málaga, Barcelona, Santander, Madrid, Marbella, Seville, Toledo, Valencia
2026-04-23
Recruiting
Amgen
Phase 1
160
Málaga, Barcelona, Valencia, Madrid
2026-04-21
Active, closed
Novo Nordisk A/S
Phase 3
606
Almería, Barcelona, León, Madrid, Málaga, Pozuelo de Alarcón, Seville
2026-04-21
Recruiting
Novo Nordisk A/S
Phase 3
400
A Coruña, Badalona, Ferrol, Madrid, Málaga, San Sebastián de Los Reyes (Madrid), Santander, Santiago de Compostela
2026-04-20
Recruiting
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 3
420
Barcelona, Madrid, Málaga, Vigo
2026-04-17
Recruiting
Mediar Therapeutics
Phase 2
85
Barcelona, Córdoba, Málaga, Valencia
2026-04-16
Recruiting
GlaxoSmithKline
Phase 2
200
Jerez de la Frontera, Badalona, Córdoba, Gijón, Madrid, Málaga, Salamanca, Vitoria-Gasteiz
2026-04-15
Recruiting
Novo Nordisk A/S
Phase 3
400
A Coruña, Badalona, Ferrol, Madrid, Málaga, San Sebastián de Los Reyes (Madrid), Santander, Santiago de Compostela
2026-04-13
Active, closed
Virtual Reality Therapy for Wrist and Hand Injury Recovery
NCT07408622Wrist Injuries, Hand and Upper Limb Trauma, Muskuloskeletan Pain
University of Malaga
Not applicable
28
Málaga
2026-04-01
Active, closed
Cortical Changes After Upper Limb Immobilization Measured by Electroencephalography
NCT07428304Wrist Injury, Hand and Upper Limb Trauma, Muskuloskeletal Diseases
University of Malaga
Observational
30
Málaga
2026-04-01
Recruiting
Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer
NCT07195227Hormon Receptor Positive Breast Cancer, Breast Cancer
DrugsCamizestrant·Ribociclib
MedSIR
Phase 2
150
Alicante, Barcelona, Girona, Granada, Jerez de la Frontera, León, Madrid, Málaga
2026-03-24
Recruiting
Hoffmann-La Roche
Phase 3
1,600
Badalona, A Coruña, Ferrol, Pozuelo de Alarcón, Barcelona, Madrid, Málaga, Seville
2026-03-23
Recruiting
Margan Biotech
Observational
100
Madrid, Málaga
2026-03-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
400
Las Palmas de Gran Canaria, Girona, Majadahonda, Barcelona, Madrid, Málaga, Seville
2026-03-18
Recruiting
Bristol-Myers Squibb
Phase 3
850
L'Hospitalet Del Llobregat, Barcelona, Madrid, Valencia, Barakaldo, Málaga, Seville, Zaragoza
2026-03-16
Recruiting
Sanofi
Phase 2/3
526
Barcelona, L'Hospitalet de Llobregat, Málaga
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
Barcelona, Santander, Pamplona, Valencia, Madrid, Málaga
2026-03-13
Recruiting
Bristol-Myers Squibb
Phase 3
750
Barcelona, Barakaldo, Jaén, Madrid, Málaga, Murcia
2026-03-12
Recruiting
Avalyn Pharma Inc.
Phase 2
160
Badalona, Granollers, Santander, Barcelona, Madrid, Málaga
2026-03-10
Recruiting
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
NCT07288398Pulmonary Hypertension Associated With HFpEF
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
540
Barcelona, Lugo, Madrid, Marbella, Málaga, Pamplona, Salamanca, Seville
2026-03-03
Recruiting
LONG NAGOMI™ PMCF STUDY
NCT07399002Coronary Artery Disease, Ischemic Heart Disease
Fundación EPIC
Observational
1,039
Cabueñes, Ciudad Real, Elche, Huelva, León, Málaga, Pamplona, Santander
2026-02-27
Active, closed
Pfizer
Phase 3
1,078
Málaga, Barcelona, Castilleja de la Cuesta, Chiclana de la Frontera, Madrid, Sanlúcar de Barrameda, Seville, Valencia
2026-02-24
Not yet open
Prevention of ANxiety and Depression Over Risk Assessment
NCT07185867Depression, Anxiety, Prevention, m-Health
The Mediterranean Institute for the Advance of Biotechnology and Health Research
Not applicable
2,595
Málaga
2026-02-15
Recruiting
Kardigan, Inc.
Phase 2/3
332
Horta-Guinardó, Majadahonda, A Coruña, Barcelona, Málaga, Murcia, Palma de Mallorca, Seville
2026-02-13
Recruiting
Eli Lilly and Company
Phase 3
800
Guadalajara, Lleida, Logroño, Madrid, Málaga, Seville
2026-02-10
Recruiting
Pfizer
Phase 1/2
224
Barcelona, Málaga, Madrid
2026-02-10
Recruiting
Virtual Reality-based Rehabilitation for Traumatic Hand and Wrist Injuries
NCT07633769Wrist Injury, Hand and Upper Limb Trauma, Hand and Forearm Trauma, Muskuloskeletal Diseases
University of Malaga
Not applicable
40
Málaga
2026-02-01
By invitation
Slow Breathing and Resistance Exercise in Fibromyalgia
NCT07404384Fibromyalgia, Fibromyalgia Syndrome
University of Malaga
Not applicable
159
Málaga
2026-02
Recruiting
Genmab
Phase 2
240
A Coruña, Barcelona, Las Palmas de Gran Canaria, Logroño, Madrid, Málaga, Pamplona, Valencia
2026-01-30
Recruiting
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
DrugsSigvotatug vedotin·PF-08634404
Pfizer
Phase 1/2
162
Jaén, Barcelona, Jerez de la Frontera, Madrid, Málaga, Valencia, Cadiz, Granada
2026-01-30
Recruiting
ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure
NCT07484009Acute Heart Failure (AHF), Heart Failure (for Example, Fluid Overload), Heart Failure Hospitalization
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Not applicable
1,014
Madrid, Barcelona, Córdoba, Girona, Málaga, Murcia, Salamanca, Sant Joan Despí
2026-01-29
Recruiting
Generate Biomedicines
Phase 3
786
Barcelona, Málaga, Seville, Zaragoza
2026-01-20
Recruiting
Boehringer Ingelheim
Phase 3
400
Barcelona, Burgos, Elche, Jerez de la Frontera, Madrid, Majadahonda, Málaga, Pamplona
2026-01-16
Recruiting
Digitizing and Automating the Diagnostic Psychiatric Assessment Process
NCT07468214Validation Studies, Psychiatric Diagnosis
Irene Lopez Armenteros
Observational
35
Málaga
2026-01-09
Recruiting
Contineum Therapeutics
Phase 2
324
Málaga, Valencia
2026-01-08
Recruiting
Bristol-Myers Squibb
Phase 2/3
590
Barcelona, Hospitalet, Madrid, Majadahonda, Málaga, Seville, Valencia
2026-01-02
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Santiago de Compostela, Barcelona, Madrid, Pamplona, Badalona, Elche (alicante), Málaga, Salamanca
2025-12-31
Recruiting
Norgine
Phase 3
212
Ferrol, Palma de Mallorca, Sabadell, Madrid, Málaga
2025-12-29
Recruiting
Sanofi
Phase 2
144
Bilbao, Barcelona, Seville, Córdoba, Málaga
2025-12-29
Recruiting
Regeneron Pharmaceuticals
Phase 1
90
Seville, Pamplona, Madrid, Málaga
2025-12-22
Recruiting
argenx
Observational
70
Málaga, Barcelona
2025-12-19
Recruiting
argenx
Phase 2
70
Málaga, Barcelona
2025-12-19
Active, closed
Pfizer
Phase 3
3,578
Málaga, Castilleja de la Cuesta, Chiclana de la Frontera, Madrid, Sanlúcar de Barrameda, Seville, Valencia
2025-12-19
Recruiting
Merck Sharp & Dohme LLC
Phase 2/3
570
Madrid, Valencia, Barcelona, Málaga
2025-12-18
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
Palma, Barcelona, Málaga, Oviedo, Valencia
2025-12-17
Recruiting
Eli Lilly and Company
Phase 3
1,035
Alzira, Barcelona, Madrid, Málaga, Santiago de Compostela, Seville
2025-12-15
Recruiting
AstraZeneca
Phase 2
320
Barcelona, Málaga, Sabadell, Santiago de Compostela, Valencia
2025-12-15
Recruiting
Ascendis Pharma A/S
Phase 3
186
Barcelona, Madrid, Málaga, Zaragoza
2025-12-12
Recruiting
BeOne Medicines
Phase 1
86
Barcelona, Madrid, Málaga
2025-12-11
Recruiting
Pfizer
Phase 3
800
Santiago de Compostela, Málaga, Barcelona, L'Hospitalet de Llobregat, Jerez de la Frontera, Madrid, Córdoba, Valencia
2025-12-11
Recruiting
Pharmanutra S.p.a.
Phase 4
146
Barcelona, Málaga, Sant Cugat del Vallès, Zaragoza
2025-12-11
Recruiting
AbbVie
Phase 2/3
490
Santiago de Compostela, Sabadell, Barcelona, Madrid, Málaga, Valencia, Zaragoza
2025-12-10
Recruiting
ALX Oncology Inc.
Phase 2
120
Málaga, Seville, Bilbao, Barcelona, Lleida, Madrid
2025-12-10
Recruiting
Incyte Corporation
Phase 3
466
Alava, Badalona, Barcelona, Madrid, Málaga, Oviedo, Palma, Sabadell
2025-12-09
Recruiting
Boehringer Ingelheim
Phase 3
120
Barcelona, Bilbao, Málaga, Seville
2025-12-09
Recruiting
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
NCT07222488Bladder Cancer, Urinary Bladder Neoplasms
DrugMK-3120
Merck Sharp & Dohme LLC
Phase 1/2
45
Málaga, Madrid
2025-12-09
Recruiting
Hoffmann-La Roche
Phase 2
160
La Corua, Santiago de Compostela, Málaga, Seville
2025-12-05
Recruiting
Merck Sharp & Dohme LLC
Phase 2
150
Málaga, Barcelona, Madrid
2025-12-04
Recruiting
Janssen Research & Development, LLC
Observational
380
Córdoba, Jerez de la Frontera, Lugo, Málaga, Ourense, Palma de Mallorca, Santiago de Compostela, Seville
2025-12-03
Recruiting
GlaxoSmithKline
Phase 1
83
Barcelona, Madrid, Málaga
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
650
Getxo, Elche (alicante), Madrid, Málaga, Pamplona, Salamanca, Seville, Terrassa
2025-12-02
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Valencia, Barcelona, Elche, Girona, Jerez de la Frontera, Madrid, Málaga, Pamplona
2025-11-30
Recruiting
Amgen
Phase 3
750
Málaga, Barcelona, L'Hospitalet de Llobregat, A Coruña, Lugo, Majadahonda, Pamplona, Madrid
2025-11-28
Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
NCT07169851Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Eli Lilly and Company
Phase 2
204
Barcelona, Madrid, Mataró, Málaga, Reus
2025-11-28
Recruiting
Genmab
Phase 3
660
Palma de Mallorca, Barcelona, Girona, A Coruña, Madrid, Málaga, Pamplona, Valencia
2025-11-28
Recruiting
AbbVie
Phase 2
180
Málaga, A Coruña, Barcelona, Madrid
2025-11-25
Recruiting
PhenoNet, Inc.
Phase 2
105
Alicante, Barcelona, Madrid, Málaga, Seville
2025-11-25
Recruiting
Mirum Pharmaceuticals, Inc.
Phase 2
60
Barcelona, Málaga
2025-11-22
Recruiting
Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice
NCT07252765Type 2 Diabetes Mellitus (T2DM), Malnutrition, Malnourishment, Drug-Induced Diabetes
Outcomes'10
Observational
334
Santander, Huelva, Las Palmas de Gran Canaria, Madrid, Málaga, Oviedo, Seville, Valencia
2025-11-20
Recruiting
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
Barcelona, Madrid, Málaga, Seville, Valencia
2025-11-19
Recruiting
Bayer
Phase 3
111
Esplugues de Llobregat, Barcelona, Córdoba, Madrid, Málaga, Seville
2025-11-19
Recruiting
Summit Therapeutics
Phase 3
600
A Coruña, Barcelona, Córdoba, Granada, Madrid, Málaga, Palma de Mallorca, Santander
2025-11-18
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
144
Badalona, Barcelona, Córdoba, Madrid, Seville, Málaga, Valencia
2025-11-18
Recruiting
AbbVie
Observational
103
Málaga, Palma, Badalona, Santander, Cartagena, Gijón, Seville, Almería
2025-11-17
Recruiting
University of Malaga
Not applicable
50
Málaga
2025-11-15
Recruiting
UCB Biopharma SRL
Phase 3
320
Alicante, Badalona, Granada, Madrid, Manises, Málaga, Santiago de Compostela, Valencia
2025-11-14
Recruiting
Boehringer Ingelheim
Phase 3
670
A Coruña, Barcelona, Girona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga, Palma de Mallorca
2025-11-07
Recruiting
Bristol-Myers Squibb
Phase 2/3
500
Barcelona, Madrid, Majadahonda, Málaga, Seville, Valencia, Zaragoza
2025-11-05
Recruiting
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Phase 3
286
Cadiz, Córdoba, Jaén, Málaga, Valladolid
2025-11-05
Recruiting
Takeda
Observational
10
L'Hospitalet de Llobregat, Barakaldo, Barcelona, Córdoba, Madrid, Málaga, Seville
2025-11-03
Not yet open
Implementing Online Mental Health Program
NCT07066943Stress, Healthcare Workers, Mindfulness, Prevention Intervention
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Not applicable
130
Málaga
2025-11
Recruiting
AstraZeneca
Phase 3
400
A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Zaragoza
2025-10-31
By invitation
Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
NCT07287163Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure
Praxis Precision Medicines
Phase 3
700
Barcelona, Madrid, Málaga, Terrassa, Valencia
2025-10-27
Recruiting
Hoffmann-La Roche
Phase 3
600
Palma de Mallorca, Santander, Las Palmas de Gran Canaria, Pamplona, Barcelona, Madrid, Málaga, Seville
2025-10-24
Recruiting
Daiichi Sankyo
Phase 3
686
A Coruña, Barcelona, Burgos, Castellion, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga
2025-10-24
Recruiting
Novo Nordisk A/S
Phase 1
30
Barcelona, Madrid, Málaga, Salamanca, Valencia
2025-10-23
Recruiting
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
NCT07168434IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant), IBS, Mixed Symptoms
DrugSaccharomyces Boulardii
Biocodex
Phase 3
406
Barcelona, León, Madrid, Marbella, Málaga, Oviedo
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
1,630
Barcelona, Castellon, Granada, Madrid, Málaga, San Sebastián de los Reyes, Santiago de Compostela, Toledo
2025-10-22
Recruiting
A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
Zymeworks BC Inc.
Phase 1
140
Barcelona, Logroño, Madrid, Málaga, Pamplona
2025-10-21
Not yet open
University of Malaga
Not applicable
20
Málaga
2025-10-20
Recruiting
GlaxoSmithKline
Phase 3
1,196
Barcelona, Málaga, Palma de Mallorca
2025-10-20
Recruiting
Bristol-Myers Squibb
Phase 1/2
540
Málaga, Badalona, Barcelona, Pamplona, Madrid
2025-10-15
Recruiting
Chronobiology and Enteral Nutrition
NCT07554716Hospitalised Patients With Enteral Nutrition
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Not applicable
60
Málaga
2025-10-10
Recruiting
CatalYm GmbH
Phase 2
131
Jaén, Málaga, Seville, Barcelona, Santiago de Compostela, Girona, Logroño, Madrid
2025-10-07
Recruiting
Pfizer
Phase 2/3
982
Barcelona, Madrid, Oviedo, Málaga
2025-10-03
By invitation
Central Sensitization Syndromes and Post-Traumatic Stress in Women: Psychological Profile and Intervention
NCT07313280Posttraumatic Stress Symptom, Central Sensitization, Chronic Pain Syndrome
University of Malaga
Not applicable
12
Málaga
2025-10-02
Recruiting
University of Campania Luigi Vanvitelli
Phase 3
480
Barcelona, Cartagena, Córdoba, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona
2025-10-01
Recruiting
BioNTech SE
Phase 1/2
880
Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia
2025-09-22
Recruiting
Bristol-Myers Squibb
Phase 3
3,040
Badalona, Barcelona, Las Palmas de Gran Canaria, Alcorcón, Málaga, Salamanca, Seville, Madrid
2025-09-22
Recruiting
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
NCT07140016Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
DrugGilteritinib
Astellas Pharma Global Development, Inc.
Phase 1
40
Barcelona, Madrid, Málaga
2025-09-22
Recruiting
Zydus Therapeutics Inc.
Phase 2
240
Alicante, Barcelona, Málaga, Valencia
2025-09-17
Recruiting
Sanofi
Phase 3
942
Mérida, L'Hospitalet de Llobregat, Jerez de la Frontera, Benalmádena, Cáceres, Málaga, Palma, Seville
2025-09-16
Active, closed
AstraZeneca
Phase 3
68
A Coruña, Badajoz, Barakaldo, Barcelona, Madrid, Málaga, Oviedo, Santander
2025-09-15
Active, closed
Eli Lilly and Company
Phase 3
800
A Coruña, Barcelona, Málaga, Santander, Santiago de Compostela, Seville, Valladolid
2025-09-15
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
A Coruña, Elche, Barcelona, Hospitalet, Donostia / San Sebastian, Madrid, Málaga, Valencia
2025-09-11
Recruiting
Janssen Research & Development, LLC
Phase 3
220
A Coruña, Barcelona, Cadiz, Castellon, Ferrol, Jerez de la Frontera, Madrid, Málaga
2025-09-10
Recruiting
AbbVie
Observational
700
Málaga, León, Cartagena, El Palmar, Murcia, Pontevedra, Toledo
2025-09-09
Recruiting
Bristol-Myers Squibb
Phase 2
182
Barcelona, Hospitalet, Madrid, Málaga, Seville, Valencia
2025-09-09
Recruiting
Early Double Sequential Defibrillation in Out of Hospital Cardiac Arrest
NCT07174986Out of Hospital Cardiac Arrest, Ventricular Fibrillation, Defibrillation, CPR
Gabriel Riva
Phase 2/3
916
Málaga, Bilbao, Barcelona, Madrid
2025-09-08
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pamplona, Santander, Seville
2025-09-08
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Barcelona, Jerez de la Frontera, Madrid, Málaga
2025-09-02
Recruiting
University of Malaga
Not applicable
40
Málaga
2025-09-01
Recruiting
Francisco J. Blanco
Not applicable
184
A Coruña, Alava, Barcelona, Madrid, Málaga, San Cristóbal de La Laguna
2025-08-28
Recruiting
Mirum Pharmaceuticals, Inc.
Phase 3
172
Almería, Barcelona, Madrid, Málaga, Santander, Vigo
2025-08-27
Recruiting
Merz Therapeutics GmbH
Phase 3
990
Barcelona, Madrid, Málaga, Seville, Terrassa, Valencia, Vigo, Zaragoza
2025-08-21
Recruiting
Merz Therapeutics GmbH
Phase 3
780
Barcelona, Madrid, Málaga, Seville, Terrassa, Valencia, Vigo, Zaragoza
2025-08-21
Active, closed
Hoffmann-La Roche
Phase 2
330
Seville, Santander, Castilleja de la Cuesta, A Coruña, Ferrol, Malaga, Málaga, Barcelona
2025-08-19
Active, closed
Amgen
Phase 3
350
Málaga, Barcelona, Majadahonda, Valencia, Madrid
2025-08-18
Recruiting
Chronobiology and Home Parenteral Nutrition Study. CHRONO-HPN Study
NCT07554703Patients With Home Parenteral Nutrition
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Not applicable
20
Málaga
2025-08-18
Recruiting
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase 1
15
Zaragoza, Barcelona, Santander, Córdoba, Donostia / San Sebastian, Madrid, Málaga, Pamplona
2025-08-08
Recruiting
AstraZeneca
Phase 2
278
A Coruña, Madrid, Manresa, Málaga, Santander, Valencia
2025-08-07
Recruiting
AstraZeneca
Phase 3
700
Barcelona, Girona, Madrid, Majadahonda, Málaga, Oviedo, Sabadell, Santander
2025-08-06
Recruiting
Pfizer
Phase 3
400
A Coruña, Barcelona, Bilbao, Málaga, Granada, Jaén, Zaragoza
2025-08-05
Active, closed
Footwear and Brain Activity in Children
NCT07151352Foot, Footwear, Children
University of Malaga
Not applicable
37
Málaga
2025-08-01
Recruiting
AstraZeneca
Phase 3
800
Badalona, Barcelona, Córdoba, El Palmar (Murcia), L'Hospitalet de Llobregat, Madrid, Málaga, Oviedo
2025-08-01
Recruiting
CatalYm GmbH
Phase 2
107
Jaén, Málaga, Seville, Santander, Barcelona, Pamplona, Santiago de Compostela, Rioja
2025-08-01
Recruiting
Amgen
Phase 3
12,800
Castilleja de la Cuesta, Córdoba, Jaén, Málaga, Seville, San Cristóbal de La Laguna, Santander, Badalona
2025-07-25
Active, closed
Windward Bio
Phase 2
136
Chiclana de la Frontera, Madrid, San Sebastián, Pozuelo de Alarcón, Benalmádena, Málaga, Seville
2025-07-24
Recruiting
AstraZeneca
Phase 2
100
Barcelona, Elche, Madrid, Málaga, Ourense, Oviedo, Santander, Valencia
2025-07-17
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
A Coruña, Badalona, Barcelona, Girona, Madrid, Málaga, Seville
2025-07-17
Active, closed
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Barcelona, Esplugues de Llobregat, Donostia / San Sebastian, Madrid, Málaga, Murcia
2025-07-14
Recruiting
Bristol-Myers Squibb
Phase 3
426
Getxo, Elche (alicante), Madrid, Málaga, Pamplona, Salamanca, Seville, Terrassa
2025-07-10
Recruiting
Single-cell Immune Response to Controlled Gluten Ingestion in Pediatric Celiac Disease
NCT07362654Celiac Disease, Gluten Sensitivity, Autoimmune Diseases
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Not applicable
51
Málaga
2025-07-07
Recruiting
NIMA-Colon Cancer Study
NCT07534852Colon Cancer
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Not applicable
120
Málaga
2025-07-01
Active, closed
Pfizer
Phase 1/2
74
Barcelona, Madrid, Málaga, Valencia, Granada
2025-06-30
Recruiting
AstraZeneca
Phase 2
987
Benalmádena, Granollers, Madrid, Málaga, Mérida, Pozuelo de Alarcón, Santander
2025-06-27
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
DrugMaridebart cafraglutide
Amgen
Phase 3
5,056
Córdoba, Málaga, Las Palmas de Gran Canaria, Badalona, Barcelona, L'Hospitalet de Llobregat, Lleida, A Coruña
2025-06-25
Active, closed
DBV Technologies
Phase 3
480
Barcelona, Madrid, Málaga, Santiago de Compostela
2025-06-24
Recruiting
Novartis Pharmaceuticals
Phase 3
400
El Palmar, Valencia, Barcelona, Córdoba, Madrid, Málaga, Seville
2025-06-23
Active, closed
Incyte Corporation
Phase 3
159
Alicante, Barcelona, Esplugues de Llobregat, Granada, Madrid, Manises, Málaga, Santiago de Compostela
2025-06-17
Recruiting
GlaxoSmithKline
Phase 1/2
85
Badajoz, Barcelona, Madrid, Málaga, Pozuelo de AlarcOn Madr
2025-06-12
Recruiting
GlaxoSmithKline
Phase 2
80
Barcelona, Madrid, Málaga, Ourense, PamplonaNavarra, Salamanca, Valencia
2025-06-05
Recruiting
AstraZeneca
Phase 3
15,100
A Coruña, Alicante, Barcelona, Cáceres, Huelva, Madrid, Málaga, Murcia
2025-06-04
Active, closed
Incyte Corporation
Phase 3
9
Badalona, Barcelona, El Palmar, Esplugues de Llobregat, Granada, Las Palmas de Gran Canaria, Madrid, Málaga
2025-06-04
Active, closed
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
NCT07037277HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C
DrugsBemnifosbuvir-Ruzasvir·BEM/RZR·Sofosbuvir-Velpatasvir
Atea Pharmaceuticals, Inc.
Phase 3
880
Santander, Málaga, Vigo, Barcelona
2025-06-02
Not yet open
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Observational
32
Málaga
2025-06
Recruiting
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Observational
750
Málaga
2025-06
Recruiting
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Not applicable
20
Málaga
2025-05-29
Active, closed
Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)
NCT06931405Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Blueprint Medicines Corporation
Phase 2
105
Barcelona, Málaga
2025-05-28
Recruiting
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
NCT05815927Oligometastatic Squamous Cell Carcinoma of the Head and Neck
DrugPembrolizumab
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
200
Badalona, Barakaldo, Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga
2025-05-23
Active, closed
Swedish Orphan Biovitrum
Phase 4
252
Salamanca, A Coruña, Barcelona, Málaga, Palma de Mallorca, Zaragoza
2025-05-21
Recruiting
Pfizer
Phase 2
252
Santander, Madrid, Pozuelo de Alarcón, Málaga
2025-05-20
Recruiting
The Cooling Sensation Safe Deglution Study
NCT06936501Neuromotor Dysphagia After Acute Stroke
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Not applicable
15
Málaga
2025-05-19
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
450
Badajoz, Barakaldo, Barcelona, Cadiz, Córdoba, Granada, Madrid, Málaga
2025-05-19
Recruiting
Corxel Pharmaceuticals
Phase 2/3
740
A Coruña, Albacete, Barcelona, Girona, Madrid, Málaga, Seville, Valencia
2025-05-15
Recruiting
Ultrasound-Innovation Medtech, S.L.
Not applicable
457
A Coruña, Barcelona, Bilbao, Donostia / San Sebastian, Granada, Las Palmas de Gran Canaria, Madrid, Málaga
2025-05-10
Active, closed
Hoffmann-La Roche
Phase 2
285
Seville, Santander, Castilleja de la Cuesta, A Coruña, Barcelona, Málaga
2025-05-05
Recruiting
BioNTech SE
Phase 1/2
594
Barcelona, Córdoba, Málaga, Seville, Torrejón de Ardoz, Valencia
2025-05-02
Recruiting
Optimising TREATment for Severe Gram-Negative Bacterial Infections
NCT07004049Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia, Carbapenem Resistant Bacterial Infection
DrugsCeftolozane-tazobactam·Cefiderocol·Fosfomycin·Meropenem-Vaborbactam
National University of Singapore
Phase 4
600
Alicante, Badajoz, Barakaldo, Barcelona, Córdoba, Granada, Madrid, Málaga
2025-04-21
Recruiting
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Phase 2
340
Granada, Barcelona, Santander, Madrid, Málaga
2025-04-17
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
605
L'Hospitalet de Llobregat, Majadhonda, Madrid, Valencia, Barcelona, Málaga
2025-04-15
Recruiting
Société des Produits Nestlé (SPN)
Not applicable
400
A Coruña, Almería, Barcelona, Madrid, Málaga, Seville, Tarragona, Zaragoza
2025-04-10
Recruiting
Hoffmann-La Roche
Phase 3
450
Elche, L'Hospitalet de Llobregat, Pamplona/iruña, Bilbao, Barcelona, Madrid, Málaga, Seville
2025-04-09
Recruiting
Epygenix
Phase 3
260
Barcelona, Madrid, Málaga, Pamplona, Seville
2025-04-09
Recruiting
Gilead Sciences
Phase 3
695
A Coruña, Barcelona, Girona, Jaén, Las Palmas de Gran Canaria, Madrid, Málaga, Seville
2025-04-04
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Barcelona, Majadahonda, Pamplona, Málaga, Valencia
2025-04-01
Recruiting
Eli Lilly and Company
Phase 3
700
Badajoz, Barcelona, Hospitalet, Jerez de la Frontera, Las Palmas de Gran Canaria, Madrid, Málaga, Palma
2025-03-27
Recruiting
Daiichi Sankyo
Phase 3
510
Burgos, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Ourense, Oviedo, Pamplona
2025-03-27
Recruiting
AstraZeneca
Phase 2
540
Barcelona, Madrid, Málaga, Mérida, Patraix, Santander
2025-03-26
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
270
L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga
2025-03-25
Recruiting
Bayer
Phase 1/2
450
Barcelona, Logroño, Madrid, Pozuelo de Alarcón, Málaga, Valencia, Pamplona
2025-03-21
Active, closed
Immutep S.A.S.
Phase 3
756
Badalona, Barcelona, Córdoba, Madrid, Málaga, Oviedo, Sabadell, Seville
2025-03-21
Recruiting
AstraZeneca
Phase 3
990
Barakaldo, Barcelona, Granada, Madrid, Málaga, Palma de Mallorca, Pamplona, Seville
2025-03-18
Recruiting
AstraZeneca
Phase 3
11,300
A Coruña, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Sant Joan Despí, Santiago(A Coruña)
2025-03-14
Recruiting
AstraZeneca
Phase 2
80
Barcelona, Madrid, Málaga, Pamplona, Santander, Valencia
2025-03-12
Recruiting
AbbVie
Phase 1/2
252
Santander, Seville, A Coruña, Alicante, Barcelona, Málaga
2025-03-06
Recruiting
GlaxoSmithKline
Phase 1/2
305
A Coruña, Barcelona, Madrid, Málaga, Valencia, Zaragoza
2025-03-04
Recruiting
Takeda
Phase 3
1,088
Mérida, Sabadell, Santiago de Compostela, Málaga, Seville, Valencia
2025-03-03
Recruiting
AstraZeneca
Phase 3
5,000
A Coruña, Almería, Badalona, L'Hospitalet de Llobregat, Majadahonda, Málaga, Palma deMallorca, Pamplona
2025-03-03
Recruiting
Centro de Emergencias Sanitarias 061 Andalucía
Observational
5,000,000
Málaga
2025-03-01
Recruiting
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
NCT06517875Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
DrugsMomelotinib·Reblozyl·Luspatercept
GlaxoSmithKline
Phase 2
68
Badalona, Barcelona, Las Palmas, Madrid, Málaga, Valencia
2025-02-28
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
327
Eixample, L'Hospitalet de Llobregat, Madrid, Barcelona, Málaga
2025-02-27
Recruiting
Daiichi Sankyo
Phase 3
726
Badalona, Barcelona, Córdoba, Elche, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia
2025-02-27
Active, closed
Janssen Research & Development, LLC
Phase 3
552
A Coruña, Barcelona, Córdoba, Madrid, Málaga, Sabadell, Santander, Seville
2025-02-21
Active, closed
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
DrugIMVT-1402
Immunovant Sciences GmbH
Phase 2
56
Badalona, Pamplona, Burjassot, Madrid, Málaga
2025-02-19
Recruiting
Menarini Group
Phase 2
44
Barcelona, Cadiz, Girona, Madrid, Málaga, Santiago de Compostela
2025-02-18
By invitation
Longboard Pharmaceuticals
Phase 3
324
Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga, Valencia
2025-02-12
Active, closed
GlaxoSmithKline
Phase 2
307
Alcorcon Madrid, Barcelona, Benalmádena, Jerez de la Frontera, Madrid, Málaga, Santander, Seville
2025-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Barcelona, Lleida, Madrid, Málaga, Valencia
2025-02-07
By invitation
Effectiveness of 5-week Digital Respiratory Practice in Children With Duchenne and Becker Muscular Dystrophies.
NCT06363526Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Muscular Dystrophy
University of Malaga
Not applicable
12
Málaga
2025-02-05
Recruiting
LEO Pharma
Phase 3
90
Barcelona, Madrid, Málaga
2025-02-05
Recruiting
Bristol-Myers Squibb
Phase 1/2
416
Santiago de Compostela, Barcelona, Hospitalet, Madrid, Majadahonda, Valencia, Málaga, Seville
2025-02-04
Recruiting
Airway Therapeutics, Inc.
Phase 2/3
366
Alicante, Barcelona, Bilbao, Cadiz, Lleida, Madrid, Málaga, Santiago de Compostela
2025-02-03
Recruiting
BioNTech SE
Phase 3
621
Badajoz, Barcelona, Castellon, León, Madrid, Málaga, Seville, Torrejón de Ardoz
2025-02-03
Recruiting
AbbVie
Observational
1,200
Málaga, Lorca, Vigo, Seville, Granada, Huelva, Madrid, Murcia
2025-01-31
Active, closed
MedSIR
Phase 1/2
76
Barcelona, Granada, Madrid, Málaga, Valencia
2025-01-17
Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer
DrugZanidatamab
Jazz Pharmaceuticals
Phase 2
200
Málaga
2025-01-14
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
DrugOcrelizumab
Amgen
Phase 3
152
Alcorcón, Barcelona, Castilleja de la Cuesta, Dénia, Madrid, Malag, Málaga, Salt
2025-01-13
Recruiting
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Not applicable
62
Málaga
2025-01-13
Active, closed
Immunovant Sciences GmbH
Phase 2
120
Barcelona, Bilbao, Málaga, Seville
2025-01-10
Recruiting
Janssen Research & Development, LLC
Phase 3
750
A Coruña, Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Santander, Santiago de Compostela, Seville
2025-01-09
Active, closed
Daiichi Sankyo
Phase 2
335
A Coruña, Barcelona, Madrid, Málaga
2025-01-06
Active, closed
Prehospital Emergency Airway Research.
NCT07289139Airway Management, Emergency
Centro de Emergencias Sanitarias 061 Andalucía
Observational
4,300
Málaga
2025-01-01
Active, closed
mAbxience Research S.L.
Phase 3
726
A Coruña, Barcelona, Madrid, Málaga, Murcia, Oviedo, Palma de Mallorca, Pontevedra
2024-12-30
Recruiting
Fundación para la Investigación Biosanitaria del Principado de Asturias
Not applicable
250
Alicante, Barcelona, L'Hospitalet de Llobregat, Santander, Córdoba, Las Palmas de Gran Canaria, Madrid, Málaga
2024-12-24
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
32
Málaga, Madrid
2024-12-20
Active, closed
argenx
Phase 3
154
Alicante, Badalona, Barcelona, Madrid, Málaga, San Sebastián
2024-12-18
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca
2024-12-17
Recruiting
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
NCT06747585Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
Alentis Therapeutics AG
Phase 1/2
170
PAU de Sanchinarro, Pozuelo de Alarcón, Barcelona, Madrid, Málaga, Seville, Valencia
2024-12-16
Recruiting
GlaxoSmithKline
Phase 3
520
Badalona, Barcelona, Gijón, Madrid, Málaga, Murcia, Salamanca, Santander
2024-12-16
Recruiting
Spanish Oncology Genito-Urinary Group
Observational
500
Albacete, Alicante, Almería, Córdoba, Granada, Jaén, Jerez de la Frontera, Málaga
2024-12-13
Active, closed
GlaxoSmithKline
Phase 1/2
14
Barcelona, Madrid, Málaga
2024-12-13
Active, closed
Novartis Pharmaceuticals
Phase 1/2
28
Barcelona, Madrid, Málaga
2024-12-12
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Badajoz, Barcelona, Madrid, Málaga, Pamplona, Seville, Valencia
2024-12-12
Recruiting
Novartis Pharmaceuticals
Phase 3
60
Elche, Cadiz, Badalona, Esplugues, Pamplona, Barcelona, Málaga, Seville
2024-12-09
Active, closed
Amgen
Phase 3
707
Málaga, Seville, Barcelona, Pamplona, Valencia, Madrid
2024-12-09
Active, closed
Kumquat Biosciences Inc.
Phase 1
13
Málaga, L'Hospitalet de Llobregat, Madrid
2024-12-09
Active, closed
PPM Services S.A.
Phase 3
400
Alcorcón, Barcelona, Esplugues de Llobregat, Granada, Madrid, Málaga, Seville, Valencia
2024-12-05
Recruiting
Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression
NCT06180356Ovarian Cancer, Oligometastatic Disease, Serous Ovarian Tumor
DrugNiraparib
MedSIR
Phase 2
30
A Coruña, Barakaldo, Barcelona, Girona, Jaén, Madrid, Málaga, Oviedo
2024-12-03
By invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugVutrisiran
Alnylam Pharmaceuticals
Phase 3
700
Barcelona, Bilbao, L'Hospitalet de Llobregat, Madrid, Málaga
2024-12-03
Active, closed
ViiV Healthcare
Phase 3
326
L'Hospitalet de Llobregat, Bilbao, Puerto Real, Barcelona, Córdoba, Madrid, Málaga, Murcia
2024-12-02
Active, closed
AbbVie
Observational
1,314
Málaga, L'Hospitalet de Llobregat, Leganés, Majadahonda, Oviedo, Seville, Barcelona, Madrid
2024-11-26
Recruiting
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
NCT06458712Advanced Cancers (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Mets) With Specific Mutations (Homologous Recombination Deficiency)
Duke Street Bio Ltd
Phase 1
180
Logroño, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia
2024-11-21
Recruiting
UCB Biopharma SRL
Phase 3
450
A Coruña, Badajoz, Barcelona, Castellon, Madrid, Málaga, Mérida, Sabadell
2024-11-21
Recruiting
Eli Lilly and Company
Phase 3
125
Barcelona, Madrid, Málaga, Sabadell, Seville, Vitoria-Gasteiz
2024-11-18
Active, closed
Sanofi
Observational
143
Santiago de Compostela, Esplugues de Llobregat, Oviedo, Seville, Alicante, Barcelona, Madrid, Málaga
2024-11-14
Recruiting
Genentech, Inc.
Phase 1
410
Barcelona, Madrid, Málaga, Seville, Valencia
2024-11-14
Active, closed
Longboard Pharmaceuticals
Phase 3
367
Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga, Valencia
2024-11-11
Recruiting
University of Cadiz
Not applicable
72
Málaga
2024-11-11
Active, closed
Amgen
Phase 2
409
Castilleja de la Cuesta, Málaga, Lleida, A Coruña, Alzira
2024-11-07
Active, closed
Sanofi
Phase 2
556
Santiago de Compostela, Badalona, Santander, Barcelona, Madrid, Benalmádena, Girona, Málaga
2024-11-07
Recruiting
Hospital Universitario 12 de Octubre
Not applicable
440
Bilbao, Granada, Huelva, Madrid, Málaga, Seville
2024-11-01
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Santiago Compostela, Santander, Pamplona, Barcelona, Córdoba, Madrid, Málaga, Salamanca
2024-10-29
Recruiting
Intra-Cellular Therapies, Inc.
Phase 2
320
Albacete, Badalona, Málaga, Zamora, Zaragoza
2024-10-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Canarias, A Coruña, Pozuelo de Alarcón, Barcelona, Madrid, Málaga
2024-10-21
Active, closed
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor
Drugs5Fluorouracil·Leucovorin·Irinotecan·Cetuximab
Eli Lilly and Company
Phase 1
750
Barcelona, Madrid, Málaga
2024-10-21
Active, closed
MoonLake Immunotherapeutics AG
Phase 3
600
A Coruña, Alcobendas, Bilbao, Castellon, Madrid, Málaga, Sabadell, Santiago de Compostela
2024-10-15
Active, closed
MoonLake Immunotherapeutics AG
Phase 3
960
A Coruña, Alcobendas, Bilbao, Castelló, Madrid, Málaga, Sabadell, Santiago de Compostela
2024-10-15
Active, closed
Incyte Corporation
Phase 2
130
Barcelona, El Palmar, Granada, Granvia de L'hospitalet 199-203, Madrid, Málaga, Salamanca, Santander
2024-10-11
Active, closed
Gilead Sciences
Phase 3
609
A Coruña, Barcelona, Málaga
2024-10-09
Recruiting
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 4
284
Alava, Barakaldo, Barcelona, Donostia / San Sebastian, Granada, Logroño, Madrid, Málaga
2024-10-09
Recruiting
Novartis Pharmaceuticals
Phase 2
200
Málaga, Valencia, Barcelona, Madrid, Salamanca
2024-10-09
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
A Coruña, Barcelona, L'Hospitalet de Llobregat, Palma, Madrid, Majadahonda, Valencia, Málaga
2024-10-07
Recruiting
Amgen
Phase 1
220
Málaga, Barcelona, Valencia, Madrid
2024-10-07
Recruiting
AstraZeneca
Phase 3
744
A Coruña, Barakaldo, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga
2024-10-04
Recruiting
GlaxoSmithKline
Phase 1
845
Badajoz, Barcelona, Madrid, Málaga, Valencia, Zaragoza
2024-09-30
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Majadahonda, Málaga, Lleida, Madrid, Salamanca, Seville, Valladolid, Zaragoza
2024-09-26
Active, closed
Longboard Pharmaceuticals
Phase 3
96
Esplugues de Llobregat, Pamplona, Barcelona, Madrid, Málaga
2024-09-25
Active, closed
Hoffmann-La Roche
Phase 3
338
L'Hospitalet de Llobregat, Seville, Barcelona, Madrid, Málaga, Valencia, Zaragoza
2024-09-23
Active, closed
Regeneron Pharmaceuticals
Phase 2
151
Granada, Málaga, Palma, Badalona, Barcelona, El Palmar, Oviedo, Madrid
2024-09-18
Recruiting
GlaxoSmithKline
Phase 3
440
Pamplona Iruna, Barcelona, Córdoba, Granada, Madrid, Málaga, Santander, Seville
2024-09-11
Active, closed
Amgen
Phase 3
315
Alicante, Barcelona, Jaén, Madrid, Mataró, Málaga, Oviedo, Seville
2024-09-09
Recruiting
PETHEMA Foundation
Phase 2
106
Alicante, Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Marbella, Málaga, Oviedo
2024-09-02
Active, closed
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
NCT06331299Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
UroGen Pharma Ltd.
Phase 3
99
Málaga, Barcelona, Madrid
2024-08-29
Active, closed
Sanofi
Phase 2
229
Barcelona, Chiclana de la Frontera, Las Palmas de Gran Canaria, Seville, Madrid, Málaga
2024-08-29
Active, closed
Gilead Sciences
Phase 3
640
A Coruña, Barcelona, Jaén, Madrid, Málaga, Palma, Sabadell, San Sebastián
2024-08-28
Active, closed
AstraZeneca
Phase 2
194
A Coruña, Alcorcón, Barcelona, Madrid, Málaga, Pamplona, Santander, Santiago de Compostela
2024-08-27
Active, closed
Zenas BioPharma (USA), LLC
Phase 2
93
Madrid, Málaga, Murcia, Seville, Valencia
2024-08-26
Recruiting
Sanofi
Phase 3
160
Santiago de Compostela, Barcelona, Majadahonda, Pamplona, Málaga, Sabadell, Santa Cruz de Tenerife, Valencia
2024-08-21
Recruiting
Colorado Prevention Center
Phase 3
2,600
Girona, A Coruña, Santiago de Compostela, Madrid, Majadahonda, Málaga, Manises, Valencia
2024-08-20
Recruiting
AstraZeneca
Phase 3
620
Barcelona, Madrid, Málaga, Santander
2024-08-12
Recruiting
AbbVie
Phase 3
110
Ferrol, Esplugues de Llobregat, Málaga, Seville, Zaragoza
2024-08-08
Active, closed
Servier Bio-Innovation LLC
Phase 1/2
102
Barcelona, Madrid, Málaga, Valencia
2024-08-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
3,000
Málaga, Centelles, Barcelona, Figueres, A Coruña, Santiago de Compostela, Pozuelo de Alarcón, Alcorcón
2024-08-05
Recruiting
AstraZeneca
Phase 3
788
A Coruña, Barcelona, Cáceres, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona
2024-08-01
Not yet open
Lymphatic Response to Resistance Exercise in Breast Cancer Survivors
NCT06113627Breast Cancer Lymphedema, Survivorship, Lymphedema of Upper Limb
University of Malaga
Not applicable
170
Málaga
2024-08
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Santiago Compostela, L'Hospitalet de Llobregat, Alicante, Barcelona, Lleida, Madrid, Málaga, Valencia
2024-07-31
Recruiting
NovoCure GmbH
Phase 3
734
Elche, Seville, Barcelona, Torrejón de Ardoz, Lleida, Madrid, Málaga, Pamplona
2024-07-31
By invitation
Biohaven Therapeutics Ltd.
Phase 2
660
Badalona, L'Hospitalet de Llobregat, Pamplona, Vigo, Barcelona, Granada, Madrid, Málaga
2024-07-30
Recruiting
PulseSelect™ PFA Global Registry
NCT06393920Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
1,950
Córdoba, Málaga, Salamanca
2024-07-23
Recruiting
Daiichi Sankyo
Phase 1/2
123
Barcelona, Girona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Vigo
2024-07-22
Recruiting
Jazz Pharmaceuticals
Phase 3
286
Santiago de Compostela, Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville, Valencia
2024-07-19
Recruiting
Fundación IVI
Observational
1,573
Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia, Vigo, Zaragoza
2024-07-17
Recruiting
Amgen
Phase 3
450
Córdoba, Granada, Málaga, Seville, Zaragoza, Santander, Burgos, Badalona
2024-07-17
Recruiting
Colorado Prevention Center
Phase 3
1,500
A Coruña, Santiago de Compostela, Madrid, Málaga, Manises, Valencia, Barcelona
2024-07-09
Recruiting
Fundacion Oncosur
Phase 2
78
Badalona, Barcelona, Sabadell, Santander, Cadiz, Madrid, Málaga, Barakaldo
2024-07-05
Active, closed
AbbVie
Phase 3
1,400
Sabadell, Santander, Manises, Madrid, Málaga, Valencia
2024-06-27
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Badalona, Málaga, El Palmar, A Coruña, Alicante, Barcelona, Lleida, Madrid
2024-06-25
Recruiting
Boehringer Ingelheim
Phase 3
6,712
Badalona, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Málaga, Sanlúcar de Barrameda, Santiago de Compostela
2024-06-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Santiago de Compostela, Las Palmas de Gran Canaria, Málaga, Barcelona, Madrid, Seville
2024-06-10
Active, closed
Amgen
Phase 3
563
Málaga, Seville, Barcelona, L'Hospitalet de Llobregat, Pamplona, Valencia, Madrid
2024-06-05
Recruiting
Kartos Therapeutics, Inc.
Phase 3
600
Badalona, Barcelona, Cáceres, Las Palmas de Gran Canaria, Madrid, Málaga, Salamanca, Valencia
2024-06-03
Active, closed
Kumquat Biosciences Inc.
Phase 1
92
Barcelona, Madrid, Málaga, Pamplona
2024-06-03
Recruiting
Eli Lilly and Company
Phase 3
300
Barcelona, Córdoba, Madrid, Málaga, Valencia
2024-06-03
Recruiting
Harmony Biosciences Management, Inc.
Phase 3
134
Barcelona, Madrid, Málaga
2024-05-28
Recruiting
PENTA Foundation
Not applicable
3,080
Alicante, Bilbao, Málaga
2024-05-28
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
89bio, Inc.
Phase 3
762
Almería, Badalona, Barcelona, Córdoba, Madrid, Málaga, Pontevedra, Santander
2024-05-24
Recruiting
Merck Sharp & Dohme LLC
Phase 3
348
Las Palmas de Gran Canaria, Leganés, Madrid, Málaga, Barcelona, Seville
2024-05-24
Recruiting
Daiichi Sankyo
Phase 3
540
Barcelona, Córdoba, Jaén, Jerez de la Frontera, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Málaga
2024-05-21
Active, closed
Biohaven Therapeutics Ltd.
Phase 2/3
390
Badalona, L'Hospitalet de Llobregat, Pamplona, Vigo, Barcelona, Granada, Madrid, Málaga
2024-05-13
Active, closed
Eli Lilly and Company
Phase 3
10,000
A Coruña, Almería, Alzira, Barcelona, Ferrol, Málaga, Oviedo, Palma de Mallorca
2024-04-30
Recruiting
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Not applicable
100
Málaga
2024-04-28
Recruiting
Janssen Research & Development, LLC
Phase 3
641
A Coruña, Alzira, Barcelona, Cadiz, Castellon, Jerez de la Frontera, Madrid, Málaga
2024-04-18
Recruiting
Integrated Approach in Frail Older People with Atrial Fibrillation
NCT06775028Atrial Fibrillation (AF), Hypertension, Coronary Arterial Disease (CAD), Heart Failure
Heart Care Foundation
Not applicable
1,250
Alicante, Cartagena, Cártama, Elche, Málaga, Murcia, Sant Joan d'Alacant, Tarragona
2024-04-11
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Badalona, Barcelona, Madrid, Málaga, Sabadell, Santander, Seville, Valencia
2024-04-09
Active, closed
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
DrugPirfenidone
Avalyn Pharma Inc.
Phase 2
375
Granada, Barcelona, Santander, Madrid, Málaga, Oviedo, Seville, Cadiz
2024-04-03
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
A Coruña, Alcalá de Henares, Lleida, Madrid, Málaga, Murcia, Oviedo, Seville
2024-03-29
Active, closed
AstraZeneca
Phase 3
2,554
A Coruña, Almería, Badalona, L'Hospitalet de Llobregat, Lugo, Madrid, Málaga, Palma deMallorca
2024-03-29
Recruiting
Italfarmaco
Phase 3
220
Badalona, Alicante, Madrid, Málaga, Valencia
2024-03-26
Recruiting
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
NCT07699328EGFR-Mutant Non-Small Cell Lung Cancer
Voronoi, Inc
Phase 1/2
315
Badalona, L'Hospitalet de Llobregat, Madrid, Málaga
2024-03-26
Recruiting
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
Iambic Therapeutics, Inc
Phase 1
383
Barcelona, Madrid, Málaga, Seville, Valencia
2024-03-25
Recruiting
Fundación para la Investigación del Hospital Clínico de Valencia
Observational
70
Alicante, Badajoz, Barcelona, Candelaria, Castellon, Málaga, Murcia, Palma de Mallorca
2024-03-21
Recruiting
AstraZeneca
Phase 3
100
Esplugues de Llobregat, Madrid, Málaga, Santiago de Compostela, Valencia
2024-03-14
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
89bio, Inc.
Phase 3
1,350
Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pontevedra, Santander, Santiago de Compostela
2024-03-13
Active, closed
Samsung Bioepis Co., Ltd.
Phase 3
555
Leganés, Málaga, Ourense, Oviedo, Santiago de Compostela, Seville, Valencia
2024-03-12
Recruiting
Novartis Pharmaceuticals
Phase 3
50
Santiago Compostela, Barcelona, Córdoba, Málaga, Seville, Valencia
2024-02-28
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
Barcelona, Madrid, Málaga, Seville, Valencia
2024-02-26
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Palma, A Coruña, Barcelona, Alicante, Badalona, Castellon, Madrid, Málaga
2024-02-21
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Málaga, Seville, Zaragoza, Las Palmas de Gran Canaria, Badalona, Barcelona, Santiago de Compostela, Majadahonda
2024-02-20
Active, closed
Janssen Research & Development, LLC
Phase 2
305
A Coruña, Alicante, Barcelona, Jaén, Lugo, Madrid, Málaga, Seville
2024-02-16
By invitation
University of Malaga
Not applicable
83
Málaga
2024-02-15
Active, closed
Boehringer Ingelheim
Phase 3
428
A Coruña, Alicante, Barcelona, Bilbao, Madrid, Málaga, Seville, Valencia
2024-02-09
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase
DrugsBosutinib·Olverembatinib
Ascentage Pharma Group Inc.
Phase 3
333
Badalona, Barcelona, Elche, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Murcia
2024-02-05
Active, closed
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
NCT05853575Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
DrugAdagrasib
Mirati Therapeutics Inc.
Phase 2
200
Santiago de Compostela, Málaga, Palma de Mallorca, Oviedo, Barcelona, Madrid, Seville, Valencia
2024-02-01
Active, closed
Sanofi
Phase 3
260
Santander, Barcelona, Madrid, Málaga, Salamanca, Seville, Valencia
2024-01-23
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
339
Barcelona, Madrid, Seville, Valencia, Málaga, Pozuelo de Alarcón
2024-01-23
Active, closed
DualityBio Inc.
Phase 3
541
Barcelona, Sant Cugat del Vallès, Santiago de Compostela, Madrid, Majadahonda, Pozuelo de Alarcón, Málaga, Pamplona
2024-01-18
Recruiting
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
NCT06162221Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
DrugsElironrasib·RMC-9805·Cetuximab·Pemetrexed
Revolution Medicines, Inc.
Phase 1/2
616
Madrid, Pamplona, Valencia, A Coruña, Barcelona, Málaga, Seville
2024-01-18
Active, closed
Samsung Bioepis Co., Ltd.
Phase 1
163
Jaén, A Coruña, Málaga
2024-01-16
Active, closed
International Non-selection Study for ERA® Test in Patients With Previous Implantation Failures
NCT06097559Infertility of Uterine Origin, Implantation Failure
Igenomix
Observational
738
Madrid, Marbella, Málaga, Seville, Valladolid
2024-01-16
Recruiting
Hospital Universitario Central de Asturias
Observational
100
A Coruña, Badalona, Barcelona, Burgos, Donostia / San Sebastian, Madrid, Málaga, Oviedo
2024-01-12
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugCliramitug
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
A Coruña, Barcelona, El Palmar, Jaén, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga
2024-01-11
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugsErbitux·Cetuximab
AVEO Pharmaceuticals, Inc.
Phase 3
410
Alicante, Badalona, Barcelona, Cadiz, Madrid, Málaga, Santander, Valencia
2024-01-11
Recruiting
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Phase 2
75
Pozuelo de Alarcón, A Coruña, Madrid, Málaga, Seville, Valencia
2024-01-11
Recruiting
Ryvu Therapeutics SA
Phase 2
98
Barcelona, Cáceres, Madrid, Málaga, Pamplona, Seville, Valencia
2024-01-05
Active, closed
Merck Sharp & Dohme LLC
Phase 3
340
Badalona, L'Hospitalet Del Llobregat, Barcelona, Santiago de Compostela, Madrid, Marbella, Albacete, Málaga
2023-12-31
Recruiting
Bristol-Myers Squibb
Phase 1/2
460
Málaga, Barcelona, Madrid, Pamplona, Salamanca
2023-12-29
Active, closed
Bristol-Myers Squibb
Phase 3
190
A Coruña, Santiago de Compostela, Barcelona, Madrid, Majadahonda, Málaga, Seville, Valencia
2023-12-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Sabadell, Barcelona, Girona, A Coruña, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Burgos, Málaga
2023-12-18
Recruiting
Janssen-Cilag Ltd.
Observational
900
Ávila, Granada, Madrid, Málaga, Valencia, Vigo
2023-12-18
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
Barcelona, A Coruña, Madrid, Málaga, Jaén
2023-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Jerez de la Frontera, A Coruña, Pozuelo de Alarcón, Málaga, Valencia, Barcelona, Madrid, Santa Cruz de Tenerife
2023-12-15
Recruiting
Intellia Therapeutics
Phase 3
1,200
A Coruña, Barcelona, Majadahonda, Málaga, Palma de Mallorca
2023-12-13
Recruiting
Regeneron Pharmaceuticals
Phase 3
822
Santiago de Compostela, Málaga, Seville, Palma, Barakaldo, Santander, A Coruña, Pozuelo de Alarcón
2023-12-12
Recruiting
AbbVie
Phase 3
110
Ferrol, Madrid, Málaga
2023-12-11
Active, closed
Sanofi
Phase 2
197
Barcelona, Esplugues de Llobregat, Oviedo, Seville, Málaga, Valencia, Vitoria-Gasteiz
2023-12-11
Active, closed
Merck Sharp & Dohme LLC
Phase 3
868
L'Hospitalet de Llobregat, Pozuelo de Alarcón, Majadahonda, Málaga, Barcelona, Seville
2023-12-06
Active, closed
AstraZeneca
Phase 3
760
Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Santander
2023-12-04
Recruiting
The Viability Control of Human Endothelial Cells Before Keratoplasty (V-CHECK) Study
NCT05847387Corneal Transplant Failure, Corneal Endothelial Cell Loss
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Observational
135
Málaga
2023-12-01
Active, closed
ACADIA Pharmaceuticals Inc.
Phase 3
170
Barcelona, Madrid, Málaga
2023-11-27
Recruiting
Amgen
Phase 3
750
Málaga, Seville, Zaragoza, Palma de Mallorca, Las Palmas de Gran Canaria, Santander, Valladolid, Barcelona
2023-11-16
Active, closed
medac GmbH
Phase 2
49
Madrid, Pamplona, Barcelona, Málaga, Murcia, Valencia
2023-11-13
Recruiting
Takeda
Phase 3
80
Espluges de Llobregat, Horcajo de la Sierra, Málaga, Barcelona, Madrid
2023-11-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Barcelona, Las Palmas de Gran Canaria, Pozuelo de Alarcón, Madrid, Málaga
2023-11-12
Recruiting
AbbVie
Phase 1
325
Badalona, Pamplona, Barcelona, Madrid, Málaga, Zaragoza
2023-11-09
Active, closed
AstraZeneca
Phase 3
314
A Coruña, Barcelona, Madrid, Málaga, Valencia
2023-11-08
Active, closed
Bristol-Myers Squibb
Phase 2
227
L'Hospitalet de Llobregat, Majadahonda, El Palmar, Madrid, Málaga, Seville, Valencia
2023-11-07
Active, closed
AbbVie
Phase 3
122
Ferrol, Esplugues de Llobregat, Barcelona, Málaga
2023-11-06
Active, closed
Amgen
Phase 3
633
Seville, Badalona, Cáceres, El Palmar, Barcelona, Madrid, Málaga, Valencia
2023-11-02
Recruiting
LeonaBio
Phase 3
600
Barcelona, Córdoba, Madrid, Málaga, Pamplona, Valencia
2023-10-31
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Badalona, Barcelona, Santander, Santiago de Compostela, Málaga, Madrid, Majadahonda, Oviedo
2023-10-25
Active, closed
AstraZeneca
Phase 3
895
Alicante, Barcelona, Bilbao (Vizcaya), Madrid, Málaga, Palma
2023-10-24
Active, closed
Genentech, Inc.
Phase 2
260
Badalona, Málaga, Pamplona/iruña, Oviedo, Barcelona, Madrid
2023-10-18
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
DrugObrixtamig
Boehringer Ingelheim
Phase 2
204
Barcelona, Madrid, Málaga, Valencia
2023-10-13
Active, closed
Ipsen
Phase 3
759
Madrid, Málaga, Seville, Valencia
2023-10-12
Active, closed
Merck Sharp & Dohme LLC
Phase 3
14,550
Torrevieja, Córdoba, Málaga, Seville, Calella, Barcelona, Centelles, L'Hospitalet de Llobregat
2023-10-09
Active, closed
Incyte Corporation
Phase 2
63
Badalona, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Seville
2023-10-09
Recruiting
Abbott Medical Devices
Observational
1,000
Badajoz, Barcelona, Huelva, Las Palmas, Majadahonda, Málaga, Valencia
2023-09-29
Active, closed
Ipsen
Phase 3
751
Barcelona, Madrid, Málaga, Valencia
2023-09-29
Recruiting
Pierre Fabre Medicament
Phase 1/2
345
Logroño, Málaga, Barcelona, Madrid, Seville
2023-09-26
Active, closed
Ad scientiam
Not applicable
336
Girona, Madrid, Málaga, Oviedo, Zaragoza
2023-09-22
Recruiting
Hoffmann-La Roche
Phase 1/2
60
Esplugues de Llobregat, Madrid, Málaga
2023-09-21
Active, closed
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
NCT05869955Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
DrugsZola-cel·Tocilizumab·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
270
Barcelona, Santander, Córdoba, Málaga
2023-09-13
Recruiting
Hoffmann-La Roche
Phase 3
230
A Coruña, Barcelona, Madrid, Málaga, Seville
2023-09-08
Recruiting
Rescue of Nephrons With ALE.F02 (RENAL-F02)
NCT06047171Glomerulonephritis Rapidly Progressive
DrugsCyclophosphamid·Rituximab
Alentis Therapeutics AG
Phase 2
80
Barcelona, Lleida, Madrid, Málaga
2023-09-07
Recruiting
Gilead Sciences
Phase 3
402
A Coruña, Alcorcón, Badalona, Barcelona, Córdoba, Málaga, Santander, Seville
2023-09-07
Active, closed
Peptomyc S.L.
Phase 1
26
Barcelona, L'Hospitalet de Llobregat, Santander, Madrid, Málaga, Zaragoza
2023-08-31
Recruiting
Ipsen
Phase 3
276
Barcelona, Madrid, Majadahonda, Málaga, Pontevedra, Sabadell, Seville, Valencia
2023-08-31
Active, closed
Cytokinetics
Phase 3
500
A Coruña, Barcelona, Madrid, Málaga, Murcia, Palma de Mallorca, Salamanca, Seville
2023-08-31
Recruiting
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
NCT05875168Advanced Solid Tumor, Metastatic Solid Tumor
Daiichi Sankyo
Phase 1/2
590
Barcelona, Madrid, Málaga, Pozuelo de Alarcón, Seville
2023-08-18
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
437
Barcelona, Logroño, Madrid, Málaga, Pamplona, Valencia
2023-08-10
Active, closed
Pfizer
Phase 3
59
Badalona, Barcelona, Jaén, Málaga, Granada, Madrid
2023-08-09
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Málaga, Barcelona, Jaén, Madrid
2023-07-31
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,089
Barcelona, Pozuelo de Alarcón, Madrid, Málaga, Valencia
2023-07-19
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
1,000
Majadahonda, Málaga, Barcelona, Lleida, Madrid, Salamanca, Seville, Valladolid
2023-07-11
Recruiting
PICAROS - Acalabrutinib RWE on 1L CLL in Spain
NCT05999877Chronic Lymphocytic Leukemia
AstraZeneca
Observational
315
Almería, Córdoba, Granada, Jaén, Marbella, Málaga, Seville, Zaragoza
2023-07-11
Recruiting
P+F Products + Features GmbH
Not applicable
267
Barcelona, Madrid, Valladolid, Majadahonda, Málaga, Oviedo
2023-07-03
Active, closed
Regeneron Pharmaceuticals
Phase 2/3
149
Santiago de Compostela, Palma, Barcelona, Majadahonda, Oviedo, Madrid, Málaga, Seville
2023-06-30
Active, closed
OncoC4, Inc.
Phase 3
630
Elche, Lugo, Madrid, Málaga, Valencia
2023-06-28
Recruiting
Hoffmann-La Roche
Phase 3
420
L'Hospitalet de Llobregat, Santiago de Compostela, San Cristóbal de La Laguna, Barcelona, Cáceres, Madrid, Málaga, Murcia
2023-06-07
Active, closed
Bristol-Myers Squibb
Phase 1/2
100
Málaga, Badalona, Pamplona, Madrid
2023-06-06
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
Barcelona, Madrid, Málaga
2023-06-05
Active, closed
Eli Lilly and Company
Phase 3
3,127
A Coruña, Ferrol, Almería, Málaga, Seville, Badalona, Barcelona, Valladolid
2023-06-05
Active, closed
ArriVent BioPharma, Inc.
Phase 3
398
Málaga, A Coruña, Barcelona, Madrid, Valencia
2023-06-01
Active, closed
Amgen
Phase 3
509
Málaga, Zaragoza, Barcelona, A Coruña, Majadahonda, Madrid
2023-05-31
Recruiting
Tango Therapeutics, Inc.
Phase 1/2
225
Barcelona, Madrid, Málaga, Seville
2023-05-26
Recruiting
Grey Wolf Therapeutics
Phase 1/2
300
Barcelona, Madrid, Málaga, Pamplona, Valencia
2023-05-21
Active, closed
Janssen Research & Development, LLC
Phase 2
68
Barcelona, Cáceres, Jerez de la Frontera, L'Hospitalet de Llobregat, Madrid, Málaga, Palma de Mallorca, Santiago de Compostela
2023-05-18
Recruiting
Takeda
Phase 3
240
Sagunto, Barcelona, Madrid, Málaga, Seville
2023-05-16
Recruiting
Novartis Pharmaceuticals
Phase 3
200
Esplugues, Sabadell, Barcelona, Córdoba, Madrid, Málaga
2023-05-11
Recruiting
University of Malaga
Not applicable
195
Almería, Barcelona, Granada, Madrid, Cartagena, Málaga
2023-05-05
Active, closed
Phase III Study of AK112 for NSCLC Patients
NCT06396065Non-Squamous Non-small Cell Lung Cancer
DrugsIvonescimab·Pemetrexed·Carboplatin
Summit Therapeutics
Phase 3
420
A Coruña, Barcelona, Las Palmas, Lugo, Madrid, Majadahonda, Málaga, Seville
2023-05-04
Recruiting
Usefulness of PET-CT for Invasive Fungal Infection
NCT05688592Invasive Fungal Infections
Puerta de Hierro University Hospital
Observational
224
Majadahonda, Barcelona, Granada, Madrid, Málaga, Murcia, Oviedo, Salamanca
2023-04-27
By invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817Focal Epilepsy, Tonic-Clonic Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
880
Barakaldo, Barcelona, Madrid, Málaga, Valencia, Valladolid
2023-04-25
Active, closed
Regeneron Pharmaceuticals
Phase 2
51
Badalona, Manresa, Castellon, Madrid, Málaga, Pamplona, Valencia
2023-04-21
Active, closed
Klus Pharma Inc.
Phase 2
356
Majadahonda, Pozuelo de Alarcón, Barcelona, Málaga, Seville, Valencia
2023-04-19
Recruiting
ADVANCED MARKER DISCOVERY S.L.
Observational
250
Málaga, Oviedo, Ourense, Madrid
2023-04-17
Active, closed
Umecrine Cognition AB
Phase 1/2
202
Barcelona, Madrid, Málaga, Pontevedra, Santander, Seville, Valencia
2023-04-14
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
A Coruña, Alicante, Barcelona, El Palmar, Lleida, Madrid, Manises, Málaga
2023-04-11
Active, closed
Evaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation
NCT05758909Aortic Valve Disease, Aortic Valve Stenosis, Heart Valve Diseases
Fundación EPIC
Observational
585
A Coruña, Alicante, Aravaca, Badalona, Barcelona, L'Hospitalet de Llobregat, Málaga, Oviedo
2023-04-04
Active, closed
Bayer
Phase 3
985
Santiago de Compostela, Santander, Barcelona, Cadiz, Madrid, Málaga, Murcia, Seville
2023-04-03
Recruiting
Iovance Biotherapeutics, Inc.
Phase 3
670
Santander, Málaga, Barcelona, Madrid, Pamplona, Seville, Valencia
2023-03-30
Recruiting
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3
1,166
Barcelona, Madrid, Málaga, Seville
2023-03-20
Active, closed
AbbVie
Phase 3
520
A Coruña, L'Hospitalet de Llobregat, Córdoba, Málaga, Pamplona, Barcelona, Girona, Madrid
2023-03-15
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Ferrol, Santiago, Santiago Compostela, Elche, Granada, Huelva, Marbella, Málaga
2023-03-09
Active, closed
Merck Sharp & Dohme LLC
Phase 3
537
Elche, Badalona, Barcelona, L'Hospitalet de Llobregat,Barcelona, Madrid, Málaga
2023-03-08
Recruiting
Takeda
Phase 3
160
Barcelona, Málaga, Santander, Seville
2023-03-06
Active, closed
DBV Technologies
Phase 3
600
Madrid, Málaga
2023-02-21
Active, closed
Gilead Sciences
Phase 2
400
Barcelona, Las Palmas de Gran Canaria, Lugo, Málaga, Seville, Valencia
2023-02-21
Recruiting
Xenon Pharmaceuticals Inc.
Phase 3
160
Madrid, Málaga, Valladolid, Valparaíso
2023-02-14
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Barcelona, Esplugues Llobregat, Madrid, Málaga
2023-02-13
Active, closed
Stemline Therapeutics, Inc.
Phase 1/2
435
A Coruña, Barcelona, Madrid, Málaga, Pozuelo de Alarcón, Valencia
2023-01-24
Active, closed
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Observational
88
Santander, Córdoba, Granada, Madrid, Málaga, Salamanca, Seville, Valencia
2023-01-23
Active, closed
Daiichi Sankyo
Phase 3
1,170
Barcelona, Lleida, Madrid, Málaga, Ourense, Seville, Valenica, Zaragoza
2023-01-11
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Barcelona, Madrid, Málaga, Sabadell Barcelona, Santander, Seville, Vigo
2023-01-02
Recruiting
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Not applicable
80
Málaga
2023-01-01
Active, closed
Exelixis
Phase 3
317
Palma de Mallorca, Majadahonda, Barcelona, Córdoba, Girona, Madrid, Málaga, Oviedo
2023-01-01
Active, closed
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
NCT05024773Bladder Carcinoma in Situ (CIS)
Fidia Farmaceutici s.p.a.
Phase 3
130
Barcelona, Valencia, Bilbao, Córdoba, Granada, Madrid, Málaga
2022-12-29
Recruiting
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
NCT05751798Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer)
OSE Immunotherapeutics
Phase 1/2
41
A Coruña, Girona, Málaga
2022-12-20
Recruiting
Immunocore Ltd
Phase 3
540
Barcelona, Madrid, Málaga, Valencia
2022-12-19
Active, closed
Amgen
Phase 3
7,297
Córdoba, Málaga, Seville, Zaragoza, León, Badalona, Barcelona, L'Hospitalet de Llobregat
2022-12-14
Active, closed
Dizal Pharmaceuticals
Phase 3
324
Barcelona, A Coruña, Girona, Jerez de la Frontera, Madrid, Málaga, Seville, Valencia
2022-12-13
Recruiting
AstraZeneca
Phase 3
3,527
Barcelona, Madrid, Majadahonda, Málaga, Ourense, Palma de Mallorca, Pamplona, Santander
2022-12-13
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
885
A Coruña, Badalona, Barcelona, Córdoba, Jaén, Madrid, Málaga, Sabadell
2022-12-13
Active, closed
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase 3
129
Barcelona, Burgos, A Coruña, Granada, Madrid, Murcia, Málaga, Salamanca
2022-12-02
Active, closed
AstraZeneca
Phase 3
1,174
Barcelona, Bilbao (Vizcaya), Elche(Alicante), Madrid, Málaga, Palma de Mallorca, Toledo, Valencia
2022-11-28
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
260
Badalona (Barcelona), Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Seville
2022-11-21
Active, closed
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
NCT05407324Amyotrophic Lateral Sclerosis
Corcept Therapeutics
Phase 2
279
Barcelona, Madrid, Málaga, Valencia
2022-11-15
Recruiting
Janssen Research & Development, LLC
Phase 2
520
A Coruña, Alicante, Barcelona, Madrid, Málaga, Seville, Valencia
2022-11-11
Recruiting
Bayer
Phase 3
100
Esplugues de Llobregat, Barcelona, Madrid, Málaga, Seville
2022-11-08
Recruiting
Pfizer
Observational
12,500
L'Hospitalet de Llobregat, Getafe, Leganés, Vigo, Valencia, Barcelona, Madrid, Málaga
2022-10-27
Recruiting
Regeneron Pharmaceuticals
Observational
500
Málaga, Sabadell, Jerez de la Frontera, Castellon, Ferrol, Vigo, Almería, Jaén
2022-10-26
Active, closed
Berotralstat Treatment in Children With Hereditary Angioedema
NCT05453968Hereditary Angioedema, Pediatric
DrugBerotralstat
BioCryst Pharmaceuticals
Phase 3
29
Madrid, Málaga
2022-10-25
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
L'Hospitalet de Llobregat, Barcelona, San Cristóbal de La Laguna, Alicante, Córdoba, Lleida, Madrid, Málaga
2022-10-24
Active, closed
Genentech, Inc.
Phase 1
165
L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga, Valencia
2022-10-20
Active, closed
GlaxoSmithKline
Phase 2
351
Badajoz, Badalona, Barcelona, Las Palmas de Gran Canar, Madrid, Málaga, PamplonaNavarra, Valencia
2022-10-14
Active, closed
Janssen Research & Development, LLC
Phase 3
864
Badalona, Barcelona, El Palmar, Jerez de la Frontera, León, Madrid, Málaga, Pamplona
2022-10-13
Recruiting
EMD Serono Research & Development Institute, Inc.
Observational
700
Barcelona, Las Palmas de Gran Canaria, Madrid, Málaga, Seville, Valencia
2022-10-04
Rows per page Showing 1–500 of 746
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-spain/city/m-laga

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 746 of those studies with a site in Málaga.

How many clinical trials are recruiting in Málaga?

367 of the 746 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 25 have not yet opened recruitment, 339 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Málaga), 746 studies
PhaseStudiesRecruitingShare
Phase 335715547.9%
Phase 21265516.9%
Phase 1/271419.5%
Observational60418%
Not applicable53297.1%
Phase 142215.6%
Phase 2/325183.4%
Phase 41271.6%

Most active sponsors

Lead sponsors with the most studies (Málaga)
Lead sponsorStudiesRecruiting
AstraZeneca6629
Janssen Research & Development, LLC307
Merck Sharp & Dohme LLC2916
Hoffmann-La Roche2810
Bristol-Myers Squibb2619
Novartis Pharmaceuticals208
GlaxoSmithKline1910
Amgen187
Eli Lilly and Company187
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud1813
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.